Sort
30,917 grants matching “tumor microenvironment”
Contributions of FGFR-Mediated Tumor-Stromal Interactions to Breast Cancer Growth and Progression
$378,466Kathryn L Schwertfeger · University Of Minnesota · R01 · FY2022 · CA
N-cadherin in Extraskeletal Osteolineage Cells Modulates Tumor Growth
$378,453Roberto Civitelli · Washington University · R01 · FY2023 · CA
Targeting heat shock factor 1 (HSF1) to increase tumor infiltrating lymphocytes in metastatic breast cancer.
$378,444Richard L Carpenter · Indiana University Indianapolis · R01 · FY2025 · CA
A Cobalt Porphyrin Nanoliposome Adjuvant for MHC-I-Restricted Cancer Peptide Vaccines
$378,438Jonathan F Lovell · State University Of New York At Buffalo · R01 · FY2021 · CA
ADAM17 in pancreatic cancer and pancreatitis
$378,431Howard C Crawford · Mayo Clinic Jacksonville · R01 · FY2014 · CA
ENHANCEMENT OF TH17-INDUCING DC VACCINATION FOR OVARIAN CANCER THROUGH PARPI-MEDIATED ACTIVATION OF INNATE IMMUNITY IN THE TUMOR MICROENVIRONMENT
$378,421University Of Arkansas For Medical Sciences · · FY2020 · Defense Health Agency
Brain Tumor Immunotherapy
$378,413Mark Gilbert · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Fingerprinting Invasive Membrane Protrusions to Discover Metastatic Signatures
$378,402Richard L. Klemke · University Of California, San Diego · R01 · FY2014 · CA
Fingerprinting Invasive Membrane Protrusions to Discover Metastatic Signatures
$378,402Richard L. Klemke · University Of California, San Diego · R01 · FY2016 · CA
Fingerprinting Invasive Membrane Protrusions to Discover Metastatic Signatures
$378,402Richard L. Klemke · University Of California, San Diego · R01 · FY2015 · CA
Iomab-ACT: A phase I/II study of 131-I apamistamab targeted lymphodepletion followed by CD19-targeted CAR T-cell therapy for patients with relapsed or refractory B-ALL or DLBCL
$378,389Mark S Berger · Actinium Pharmaceuticals, Inc. · R42 · FY2020 · CA
Tumor stromal effects of DDR2 in metastasis regulation
$378,387Gregory Longmore · Washington University · R01 · FY2022 · CA
Project 1: Targeting immunotherapy-induced resistance with DC vaccination and PD-1/CSF-1R inhibition
$378,369Robert M Prins · University Of California Los Angeles · P50 · FY2023 · CA
Project 2: Metabolism-Mediated Changes of Microvesicle Biogenesis
$378,357Richard A. Cerione · Cornell University · U54 · FY2017 · CA
Cell density effects on therapeutic sensitivity
$378,351Jayne Stommel · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA
Regulation of B cells in the CNS
$378,350Cornelia C Bergmann · Cleveland Clinic Lerner Com-Cwru · R01 · FY2022 · NS
Regulation of B cells in the CNS
$378,350Cornelia C Bergmann · Cleveland Clinic Lerner Com-Cwru · R01 · FY2021 · NS
Regulation of B cells in the CNS
$378,350Cornelia C Bergmann · Cleveland Clinic Lerner Com-Cwru · R01 · FY2023 · NS
Development and Mechanistic Studies of an Engineered Human Enzyme to Abrogate Immune Suppression due to Elevated Methylthioadenosine (MTA) by MTAP null/low Tumors
$378,348Everett Stone · University Of Texas At Austin · R01 · FY2021 · CA
STUDY OF THE ROLE OF EZH2 IN THE REGULATION OF MACROPHAGE POLARIZATION IN PROSTATE CANCER TUMORAL MICROENVIRONMENT
$378,336The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. · · FY2025 · Defense Health Agency
Systemic delivery of an oncolytic adenovirus targeting TGFβ to enhance anti-PD-1 and anti-CTLA-4 therapy for triple negative breast cancer
$378,315Weidong Xu · Endeavor Health Clinical Operations · R01 · FY2023 · CA
Exploiting Caveolae-Dependent Albumin Endocytosis to Optimize Therapy in Pancreatic Cancer
$378,304Terence Marques Williams · Ohio State University · R01 · FY2019 · CA
Signal Transduction Therapy--Basic Science
$378,296Elise C. Kohn · Division Of Clinical Sciences - Nci · ZIA · FY2011 · CA
Discovery of Gene Expression Signatures in Cancer Stroma
$378,263Robert B West · Stanford University · R01 · FY2012 · CA
Project 3: Identifying and targeting mediators of CNS metastasis from lung cancer
$378,262Don X Nguyen · Yale University · P50 · FY2022 · CA